Fig. 4.
Fig. 4. Progenitor cell yields (median, 25th, and 75th percentiles) from 3 days of leukapheresis for each treatment group are shown in (A) (GM-CFC), (B) (BFU-E), and (C) (MNC). Section I includes the 7-day treatment groups, section II includes the 20 μg/kg/d SCF and filgrastim groups, and section III the 13-day treatment groups. Only 3 patients received 30 μg/kg/d SCF and filgrastim (H); their individual progenitor cell yields were 56.20, unknown, and 149.70 × 104/kg (GM-CFC); 68.91, unknown, and 424.67 × 104/kg (BFU-E); and 13.48, 8.59, and 29.99 × 104/kg (MNC). *P < .05, comparing all other treatment groups with the filgrastim alone groups (A and B).

Progenitor cell yields (median, 25th, and 75th percentiles) from 3 days of leukapheresis for each treatment group are shown in (A) (GM-CFC), (B) (BFU-E), and (C) (MNC). Section I includes the 7-day treatment groups, section II includes the 20 μg/kg/d SCF and filgrastim groups, and section III the 13-day treatment groups. Only 3 patients received 30 μg/kg/d SCF and filgrastim (H); their individual progenitor cell yields were 56.20, unknown, and 149.70 × 104/kg (GM-CFC); 68.91, unknown, and 424.67 × 104/kg (BFU-E); and 13.48, 8.59, and 29.99 × 104/kg (MNC). *P < .05, comparing all other treatment groups with the filgrastim alone groups (A and B).

Close Modal

or Create an Account

Close Modal
Close Modal